Wednesday, July 8, 2026

Patent intelligence · US

US 9487500

Compounds and compositions thereof

granted A61KA61K31/095A61K31/506A61K31/5377
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 10
Applicant portfolio 9
Patent details — US 9487500
Jurisdiction
US
Status
granted
Grant date
Nov 8, 2016
Expiration
Nov 3, 2036
Claims
27
CPC classes
A61K, A61K31/095, A61K31/506, A61K31/5377
View on Google Patents ↗

Quick answer

US 9487500 (Compounds and compositions thereof) is held by Inhibikase Therapeutics, Inc.. Status: granted. Granted Nov 8, 2016. Expires Nov 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K31/095, A61K31/506, A61K31/5377, A61K45/06, A61P

More from Inhibikase Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11725005

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Aug 10, 2043

    granted
  2. US 11407747

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Aug 4, 2042

    granted
  3. US 10906896

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Jan 28, 2041

    granted
  4. US 10344027

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Jul 4, 2039

    granted
  5. US 10316031

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Jun 6, 2039

    granted
  6. US 10118923

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Nov 1, 2038

    granted
  7. US 9907796

    Methods of treating tumoral diseases, or bacterial or viral infections

    Inhibikase Therapeutics, Inc. · Expires Mar 1, 2038

    granted
  8. US 9828370

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Nov 23, 2037

    granted

Frequently asked questions

What is US patent 9487500?

US 9487500 (Compounds and compositions thereof) is held by Inhibikase Therapeutics, Inc.. Status: granted. Granted Nov 8, 2016. Expires Nov 3, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9487500?

Inhibikase Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.

When does US 9487500 expire?

Our index shows an expiration date of Nov 3, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.